Pathology & Laboratory Medicine

Warning message

Selective filter "Related Faculty (field_biblio_faculty) (selective)" has limited the amount of total results. Please, review you query configuration.

Publications

Filter By Faculty

Filter by Principal Investigator

2022

Koeller DR, Schwartz A, DeSimone MS, Rana HQ, Rojas-Rudilla V, Russell-Goldman E, et al. Vulvar Melanoma in association with germline MITF p.E318K variant. Cancer Genet. 2022;262-263:102-106.

Chiattone C, Civallero M, Fischer T, Miranda E, Manni M, Zing NP, et al. Characteristics and clinical outcomes of patients with ALK-positive anaplastic large cell lymphoma: Report from the prospective international T-cell lymphoma project. Hematol Oncol. 2022;40(5):953-961.

Lothion-Roy J, Haigh DB, Harris AE, Metzler VM, Alsaleem M, Toss MS, et al. Clinical and molecular significance of the RNA m6A methyltransferase complex in prostate cancer. Front Genet. 2022;13:1096071.

Bok S, Greenblatt MB. Shaping the sinuses: a novel Krt14+Ctsk+ cell lineage driving regenerative bone formation. Cell Res. 2022;32(9):791-792.

Lin M, Ku AT, Dong J, Yue F, Jiang W, Ibrahim AA, et al. STAT5 confers lactogenic properties in breast tumorigenesis and restricts metastatic potential. Oncogene. 2022;41(48):5214-5222.

Butler-Laporte G, Gonzalez-Kozlova E, Su C-, Zhou S, Nakanishi T, Brunet-Ratnasingham E, et al. The dynamic changes and sex differences of 147 immune-related proteins during acute COVID-19 in 580 individuals. Clin Proteomics. 2022;19(1):34.

Brady NJ, Patel PS, Moayedi S, Sward D. A novel source of carbon monoxide for suicide attempt. Undersea Hyperb Med. 2022;49(3):329-331.

Karamchandani DM, Gonzalez RS, Westerhoff M, Westbrook LM, Panarelli NC, Al-Nuaimi M, et al. Measuring depth of invasion of submucosa - invasive adenocarcinoma in oesophageal endoscopic specimens: how good are we? Histopathology. 2022;80(2):420-429.

Lucas F, Mata DA, Greenblatt MB, Means J, Jarolim P. A Potassium-Based Quality-of-Service Metric Reduces Phlebotomy Errors, Resulting in Improved Patient Safety and Decreased Cost. Am J Clin Pathol. 2022;157(5):789-798.

Marron TU, Fiel MI, Hamon P, Fiaschi N, Kim E, Ward SC, et al. Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 2022;7(3):219-229.